Summary
Background
Methods
Results
Conclusions
Keywords
Introduction
- Li Q.
- Guan X.
- Wu P.
- et al.
- Zhu N.
- Zhang D.
- Wang W.
- et al.
- Guan W.-J.
- Ni Z.-Y.
- Hu Y.
- et al.
- Phan L.T.
- Nguyen T.V.
- Luong Q.C.
- et al.
- Li Q.
- Guan X.
- Wu P.
- et al.
- Chang D.
- Lin M.
- Wei L.
- et al.
- Rothe C.
- Schunk M.
- Sothmann P.
- et al.
Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was flawed.2020. https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-coronavirus-wrong accessed on Feb 20, 2020.
- Wang D.
- Hu B.
- Hu C.
- et al.
Methods
Participants
Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Summary |
---|---|---|---|---|---|---|---|---|---|
Relationship with Patient 1 | Index | Younger cousin | Previous classmate | Previous classmate | Previous classmate | Previous classmate | Previous classmate | Previous classmate | - |
Age (years) | 22 | 16 | 22 | 22 | 22 | 21 | 21 | 23 | 22 (16-23) |
Male sex | Y | N | Y | Y | N | Y | Y | Y | 6/8 (75%) |
Height (cm) | 170 | 167 | 180 | 175 | 160 | 170 | 180 | 180 | 173 (160-180) |
Weight (kg) | 82 | 60 | 77 | 65 | 48 | 85 | 70 | 85 | 74 (48-85) |
Body mass index (kg/m2) | 28.4 ↑ | 21.5 | 23.8 | 21.2 | 18.6 | 29.4 ↑ | 21.6 | 26.2 ↑ | 22.7 (18.6–29.4) |
Current smoker | N | N | N | Y | N | N | N | Y | 2/8 (25%) |
Comorbidity | None | None | None | None | Chronic gastritis | Fatty liver | Chronic gastritis | None | - |
Travel to or passage through Wuhan or other potential epidemic places | Y (Wuhan) | N | N | N | N | N | N | N | 1/8 (13%) |
Days from exposure to illness onset | ≥ 4 | 3 or 7 | 3 | 1 | 4 | 2 | 2 | 1 | 2 (1-4) |
Days of serial interval | - | 4 | 2 | 0 | 3 | 1 | 1 | 0 | 1 (0-4) |
Days from illness onset to first admission | 2 | 1 | 2 | 3 | 2 | 3 | 2 | 3 | 2 (1-3) |
Days from admission of Patient 1 to admission of the underlying patient | - | 3 | 2 | 1 | 3 | 2 | 1 | 1 | 2 (1-3) |
Days from illness onset to first respiratory sample collection | 4 | 1 | 2 | 4 | 2 | 3 | 2 | 3 | 3 (1-4) |
Days from illness onset to first blood sample collection | 4 | 2 | 2 | 4 | 3 | 5 | 2 | 3 | 3 (2-5) |
Days from illness onset to first positive rRT-PCR test for SARS-CoV-2 | 4 | 1 | 2 | 4 | 2 | 3 | 2 | 3 | 3 (1-4) |
Days from illness onset to diagnosis by two positive rRT-PCR tests for SARS-CoV-2 | 5 | 2 | 3 | 5 | 3 | 4 | 3 | 4 | 4 (2-5) |
Days from first admission to transfer | 5 | 3 | 3 | 4 | 3 | 2 | - | - | 3 (2-5) |
Days from first admission to discharge | - | 16 | 18 | - | - | - | 21 | 17 | 18 (16-21) 5 For Patients 2, 3, and 8; the other patients remain in hospital. Values shown in bold indicate abnormal ones. ↑, above the upper limit of the normal range; ↓, below the lower limit of the normal range; -, not applicable; Y, Yes; N, No; rRT-PCR, real-time reverse-transcriptase polymerase-chain-reaction. |
World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. 2020. https://www.who.int/publications-detail/clinical-managementof-severe-acute-respiratoryinfection-when-novelcoronavirus-(ncov)-infection-is-suspected accessed on Feb 20, 2020.
China National Health Commission. New coronavirus pneumonia prevention and control program (4th edition). 2020. http://www.gov.cn/zhengce/zhengceku/2020-01/28/5472673/files/0f96c10cc09d4d36a6f9a9f0b42d972b.pdf accessed on Feb 20, 2020.
Statistics
Results

Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Summary 1 For symptom variables, it is shown as: number of patients with the symptom presenting on date of illness onset; number of patients with the symptom presenting before or on date of hospital admission, median (range) of the days from onset of the symptom to admission; number of patients with the symptom presenting after admission; number of patients with the symptom whose association with drug use could not be excluded; for the other variables, it is described for continuous and categorical variables, and expressed as median (range) and count/total number of patients with available data (percentage), respectively. -, not applicable; ↑, above the upper limit of the normal range; ↓, below the lower limit of the normal range; Y, Yes (symptom developed before or on admission; days from onset of the symptom through admission are shown in brackets); Y1, Yes (symptom developed on date of illness onset; days from onset of the symptom through admission are shown in brackets); Y, Yes (symptom developed after admission); Y!, (symptom developed after admission; association with drug use could not be excluded). |
---|---|---|---|---|---|---|---|---|---|
Symptoms and signs | |||||||||
Fever | Y1 (3 d) | Y1 (2 d) | Y (1 d) | Y1 (3 d) | Y1 (3 d) | N | Y1 (2 d) | Y1 (4 d) | 6; 7, 3 (1-4); 0, 0 |
Body temperature on admission (°C) | 38.0 | 37.2 | 37.0 | 37.6 | 38.2 | 37.0 | 37.4 | 37.7 | 37.5 (37.0-38.2) |
Highest body temperature (°C) | 38.4 | 38.5 | 37.7 | 38.5 | 38.2 | 37.1 | 38.0 | 38.9 | 38.5 (37.1-38.9) |
Intermittent fever | Y | Y | N | N | Y | N | N | N | 3/8 (38%) |
With chills | N | N | Y | Y | Y | N | N | N | 3/8 (38%) |
Fatigue | N | N | Y1 (3 d) | Y (1 d) | Y | N | Y1 (2 d) | Y (3 d) | 2; 4, 3 (1-3); 1, 0 |
Myalgia | Y (2 d) | N | Y1 (3 d) | N | Y | N | N | Y (2 d) | 1; 3, 2 (2-3); 1, 0 |
Cough | Y (2 d) | N | Y1 (3 d) | Y (2 d) | Y | Y1 (4 d) | Y1 (2 d) | Y (3 d) | 3; 6, 3 (2-4); 1, 0 |
Sputum production | Y (2 d) | N | Y (1 d) | Y (2 d) | N | N | N | Y (3 d) | 0; 4, 2 (1-3); 0, 0 |
Hemoptysis | Y | N | N | N | N | N | N | N | 0; 0; 1, 0 |
Sore throat | N | N | Y1 (3 d) | N | Y1 (3 d) | N | N | Y1 (4 d) | 3; 3, 3 (3-4); 0, 0 |
Nasal congestion | Y1 (3 d) | N | Y (1 d) | Y (3 d) | Y | Y (2 d) | N | Y1 (4 d) | 2; 5, 3 (1-4); 1, 0 |
Rhinorrhea | Y1 (3 d) | Y | N | N | N | Y (2 d) | N | Y1 (4 d) | 2; 3, 3 (2-4); 1, 0 |
Sneezing | N | Y | Y | Y (2 d) | N | Y (1 d) | N | Y (2 d) | 0; 3, 2 (1-2); 2, 0 |
Shortness of breath | Y | N | N | N | N | Y! | Y1 (2 d) | N | 1; 1, 2 (2-2); 2, 1 |
Chest discomfort | Y! | N | N | Y | Y | Y! | N | Y | 0; 0; 5, 2 |
Chest pain | Y | N | N | N | Y | N | N | N | 0; 0; 2, 0 |
Headache | N | Y (1 d) | N | Y (1 d) | Y (2 d) | N | N | N | 0; 3, 1 (1-2); 0, 0 |
Dizziness | Y1 (2 d) | N | N | N | N | N | N | N | 1; 1, 2 (2-2); 0, 0 |
Eye discomfort | Y1 (3 d) | N | Y (2 d) | N | N | N | N | N | 1; 2, 3 (2-3); 0, 0 |
Backache | N | N | Y1 (3 d) | N | N | N | N | N | 1; 1, 3 (3-3); 0, 0 |
Anorexia | N | N | N | N | Y (1 d) | Y (1 d) | N | Y | 0; 2, 1 (1-1); 1, 0 |
Nausea | Y! | N | Y | Y | Y (1 d) | Y (1 d) | N | Y (1 d) | 0; 3, 1 (1-1); 3, 1 |
Vomiting | Y! | N | N | Y (1 time/d) | Y! (up to 4 times/d) | Y! | N | N | 0; 0; 4, 3 |
Diarrhea | Y! (up to 6 times/d) | Y (up to 6 times/d) | Y! (2 times/d) | Y (1 time/d) | Y! (up to 4 times/d) | N | N | Y (up to 3 times/d, 3 d) | 0; 1, 3 (3-3); 5, 3 |
Abdominal discomfort | Y | N | N | N | Y (1 d) | N | N | N | 0; 1, 1; 1, 0 |
≥2 upper respiratory infection symptoms before/on admission | Y | N | Y | Y | N | Y | N | Y | 5/8 (63%) |
≥1 digestive symptom before/on admission | N | N | N | N | Y | Y | N | Y | 3/8 (38%) |
Both fever and cough before/on admission | Y | N | Y | Y | N | N | Y | Y | 5/8 (63%) |
No. of symptoms on illness onset | 5 | 1 | 5 | 1 | 2 | 1 | 4 | 4 | 3 (1-5) |
No. of symptoms before/on admission | 8 | 2 | 9 | 7 | 6 | 6 | 4 | 11 | 6 (2-11) |
Respiratory rate on admission (breaths/min) | 20 | 20 | 22 ↑ | 20 | 18 | 18 | 18 | 20 | 20 (18-22) |
Oximetry saturation on admission (%) | 97 | 97 | 98 | 97 | 96 | 97 | 98 | 98 | 97 (96-98) |
Heart rate on admission (beats/min) | 86 | 82 | 90 | 90 | 94 | 86 | 94 | 92 | 90 (82-94) |
Systolic pressure on admission (mm Hg) | 120 | 120 | 150 ↑ | 125 | 131 | 124 | 120 | 118 | 122 (118-150) |
Diastolic pressure on admission (mm Hg) | 80 | 74 | 94 ↑ | 76 | 89 | 78 | 74 | 75 | 77 (74-94) |
First chest CT findings on admission | |||||||||
Pneumonia | Y (mild) | N | Y (mild) | Y (mild) | N | Y (mild) | Y (mild) | Y (mild) | 6/8 (75%) |
Multifocal mottling, patchy shadows, and/or ground-glass opacities | Y | N | Y | Y | N | Y | Y | Y | 6/8 (75%) |
Location of pneumonia | Lower lobe of right lung | - | Lower lobe of left lung | Middle and lower lobes of right lung | - | Lower lobe of right lung | Lower lobe of right lung | Middle lobe of both lungs | - |
Bilateral lung involvement | N | - | N | N | - | N | N | Y | 1/6 (17%) |
Treatment | |||||||||
Recombinant human interferon | Y (α-1b; α-2b) | Y (α-1b) | Y (α-1b; α-2b) | Y (α-1b; α-2b) | Y (α-1b) | N | Y | Y | 7/8 (88%) |
Lopinavir | Y | N | Y | Y | Y | Y | Y | Y | 7/8 (88%) |
Ritonavir | Y | N | Y | Y | Y | Y | Y | Y | 7/8 (88%) |
Other antiviral therapy | Y (adenosine monophosphate) | Y (ribavirin; oseltamivir) | N | N | N | N | Y (arbidol; ribavirin) | N | 3/8 (38%) |
Any antiviral therapy | Y | Y | Y | Y | Y | Y | Y | Y | 8/8 (100%) |
Levofloxacin | Y | N | Y | Y | N | N | N | N | 4/8 (50%) |
Moxifloxacin | N | Y | N | N | Y | Y | N | Y | 3/8 (38%) |
Other antibiotic therapy | N | N | N | Y (ceftazidime) | N | N | N | N | 1/8 (13%) |
Any antibiotic therapy | Y | Y | Y | Y | Y | Y | N | Y | 7/8 (88%) |
Outcomes | |||||||||
Recovered | N | Y | Y | N | N | N | Y | Y | 4/8 (50%) |
Discharged | N | Y | Y | N | N | N | Y | Y | 4/8 (50%) |
Measure | Reference range | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 7 | Patient 8 | Summary 2 Summary data are count/total number of patients with available data (percentage) for abnormal values. -, not available; ↑, value above the upper limit of the normal range; ↓, value below the lower limit of the normal range; AN, all measured values were within normal range; FDCPH, Feidong County People's Hospital; FAHAMU, First Affiliated Hospital of Anhui Medical University. |
---|---|---|---|---|---|---|---|---|---|
First admitted hospital | FDCPH; FAHAMU | FDCPH | FDCPH | FDCPH | FDCPH | FDCPH | FAHAMU | FAHAMU | - |
Blood routine | |||||||||
White blood cell count (× 109 cells/L) | 4.00-10.00; 3.50-9.50 | 4.77 | 2.92 ↓ | 5.26 | 3.82 ↓ | 4.02 | 7.79 | 9.48 | ↓, 2/7 (29%) |
Absolute neutrophil count (× 109 cells/L) | 2.00-7.00; 1.80-6.30 | 3.10 | 1.20 ↓ | 3.60 | 1.40 ↓ | 2.10 | 6.64 | 7.89 ↑ | ↓, 2/7 (29%); ↑, 1/7 (14%) |
Absolute lymphocyte count (× 109 cells/L) | 0.84-4.00; 1.10-3.20 | 1.23 | 1.27 | 1.04 | 1.75 | 1.46 | 0.77 ↓ | 0.86 ↓ | ↓, 2/7 (29%) |
Red blood cell count (× 1012 cells/L) | 3.50-5.50; 4.30-5.80 | 5.97 ↑ | 4.71 | 5.76 ↑ | 4.91 | 4.32 | 5.20 | 5.20 | ↑, 2/7 (29%) |
Hemoglobin (g/L) | 110-160; 130-175 | 162 ↑ | 132 | 166 ↑ | 151 | 125 | 152 | 159 | ↑, 2/7 (29%) |
Hematocrit (%) | 37.0-50.0; 40.0-50.0 | 49.3 | 42.4 | 49.2 | 45.5 | 38.5 | 46.6 | 46.8 | AN |
Platelet count (× 109 cells/L) | 100-300; 125-350 | 217 | 209 | 218 | 132 | 246 | 165 | 219 | AN |
Coagulation function | |||||||||
Prothrombin time (sec) | 10.5-14.5; 11.0-16.0 | 10.9 | 10.4 ↓ | 11.2 | 12.0 | 11.7 | 13.9 | 15.0 | ↓, 1/7 (14%) |
Activated partial thromboplastin time (sec) | 20.0-40.0; 28.0-42.0 | 26.0 | 21.8 | 28.4 | 42.2 ↑ | 25.4 | 40.5 | 39.5 | ↑, 1/7 (14%) |
International normalized ratio | 0.80-1.20; 0.85-1.15 | 0.94 | 0.89 | 0.96 | 1.04 | 1.01 | 1.06 | 1.16 ↑ | ↑, 1/7 (14%) |
Fibrinogen (g/L) | 2.00-4.00; 2.00-4.00 | 3.76 | 2.38 | 2.95 | 2.59 | 2.41 | 3.83 | 3.47 | AN |
D-dimer (μg/L) | 0.00-0.55; 0.00-0.50 | - | - | - | 0.19 | 0.19 | 0.20 | 0.27 | AN |
Blood biochemistry | |||||||||
Total protein (g/L) | 65.0-85.0; 63.0-82.0 | 80.9 | 65.6 | 78.0 | 65.6 | 69.4 | 71.2 | 82.0 | AN |
Albumin (g/L) | 40.0-55.0; 35.0-50.0 | 53.6 | 43.4 | 53.3 | 40.4 | 42.8 | 45.5 | 47.2 | AN |
Pre-albumin (mg/L) | 200-400; - | 261 | 281 | 257 | 150 ↓ | 147 ↓ | - | - | ↓, 2/5 (40%) |
Alanine aminotransferase (U/L) | 5-50; 21-72 | 30 | 14 | 20 | 12 | 11 | 27 | 20 ↓ | ↓, 1/7 (14%) |
Aspartate aminotransferase (U/L) | 13-40; 17-59 | 29 | 22 | 24 | 16 | 18 | 24 | 29 | AN |
Alkaline phosphatase (U/L) | 40-130; 38-126 | 84 | 79 | 104 | 78 | 71 | 51 | 78 | AN |
Total bilirubin (μmol/L) | 5.0-20.0; 3.0-22.0 | 9.0 | 7.4 | 10.5 | 7.8 | 12.2 | 12.2 | 25.8 ↑ | ↑, 1/7 (14%) |
Direct bilirubin (μmol/L) | 0.0-7.0; - | 2.1 | 1.6 | 2.1 | 2.1 | 3.2 | - | - | AN |
Serum creatinine (μmol/L) | 44.0-106.0; 58.0-110.0 | 69.0 | 69.6 | 69.6 | 83.9 | 57.7 | 78.8 | 104.5 | AN |
Blood urea nitrogen (mmol/L) | 2.76-8.07; 3.20-7.10 | 4.79 | 3.84 | 5.19 | 3.07 | 3.51 | 4.10 | 4.80 | AN |
Creatine kinase (U/L) | 38-174; 55-170 | 95 | 58 | 234 ↑ | 104 | 74 | 52 ↓ | 66 | ↓, 1/7 (14%); ↑, 1/7 (14%) |
Lactate dehydrogenase (U/L) | 110-240; - | 224 | 163 | 240 | 111 | 151 | - | - | AN |
Hypersensitive troponin I (ng/mL) | -; 0.000-0.034 | - | - | - | - | - | 0.01 | 0.01 | AN |
Myoglobin (ng/mL) | -; 10-46 | - | - | - | - | - | 8 ↓ | 14 | ↓, 1/2 (50%) |
Potassium (mmol/L) | 3.50-5.30; 3.50-5.10 | 4.88 | 4.50 | 4.44 | 4.68 | 4.08 | 4.16 | 4.17 | AN |
Sodium (mmol/L) | 137.0-147.0; 137.0-145.0 | 141.2 | 140.4 | 140.9 | 141.5 | 141.8 | 138.8 | 137.4 | AN |
Calcium (mmol/L) | 2.15-2.75; 2.10-2.55 | 2.40 | 2.23 | 2.38 | 2.23 | 2.28 | 2.40 | 2.33 | AN |
Chloride (mmol/L) | 96.0-110.0; 98.0-107.0 | 107.6 | 101.0 | 103.9 | 103.0 | 101.5 | 101.3 | 95.2 ↓ | ↓, 1/7 (14%) |
Infection-associated biomarkers | |||||||||
C-reactive protein (mg/L) | 0.00-7.44; 0.00-10.00 | 8.01 ↑ | - | 4.61 | 2.59 | 6.18 | 2.65 | 1.04 | ↑, 1/6 (17%) |
Procalcitonin (ng/mL) | 0.000-0.046; 0.000-0.050 | < 0.010 | 0.032 | < 0.010 | 0.051 ↑ | 0.039 | - | 0.05 | ↑, 1/6 (17%) |
Erythrocyte sedimentation rate (mm/h) | 0-15; - | 19 ↑ | - | 6 | 20 ↑ | 7 | - | - | ↑, 1/4 (25%) |
Variable | Contact 1 | Contact 2 | Contact 3 | Contact 4 | Contact 5 | Contact 6 | Contact 7 | Contact 8 | Contact 9 |
---|---|---|---|---|---|---|---|---|---|
Baseline characteristics | |||||||||
Relationship with index patient | Uncle | Classmate | Classmate | Classmate | Classmate | Classmate | Classmate | Classmate | Classmate |
Male sex | Y | N | Y | Y | Y | Y | Y | Y | Y |
Age (years) | 43 | 23 | 23 | 21 | 23 | 21 | 23 | 23 | 24 |
Current smoker | Y | N | N | N | N | N | N | N | N |
Exposure | |||||||||
Date of exposure | Jan 19 | Jan 20 | Jan 21 | Jan 21 | Jan 21 | Jan 21 | Jan 21 | Jan 21 | Jan 21 |
Exposure place | Apartment in Feidong | Hotpot restaurant in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong |
Description of exposure place | Confined room without air conditioning | Room with air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning |
Exposure duration | 1.5 h | 1 h | 5 h | 5 h | 5 h | 5 h | 5 h | 5 h | 5 h |
Clinical characteristics | |||||||||
Fever | Y (0.5 d; Jan 27; subjective) | Y (0.5 d; Jan 26) | N | N | N | N | N | N | Y (5 h; Jan 26) |
Body temperature on admission (°C) | 36.6 | 36.6 | 36.7 | 36.2 | 36.8 | 36.7 | 36.6 | 36.7 | 36.5 |
Highest body temperature (°C) | - | 37.6 (Jan 26; self-measured) | - | - | - | - | - | - | 37.3 (Jan 26; self-measured) |
Signs on admission | |||||||||
Respiratory rate (breaths/min) | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 19 | 18 |
Oximetry saturation (%) | 98 | 97 | 97 | 97 | 97 | 97 | 96 | 98 | 98 |
Heart rate (beats/min) | 80 | 80 | 90 | 76 | 78 | 88 | 78 | 99 | 90 |
Systolic pressure (mm Hg) | 127 | 127 | 140 | 120 | 137 | 115 | 125 | 141 ↑ | 120 |
Diastolic pressure (mm Hg) | 81 | 81 | 96 ↑ | 80 | 77 | 83 | 84 | 81 | 80 |
Laboratory findings on admission | |||||||||
White blood cell count (× 109 cells/L) | 4.62 | 4.08 | 5.99 | 3.84 ↓ | 8.19 | 6.55 | 5.99 | 3.76 ↓ | 8.99 |
Neutrophil count (× 109 cells/L) | 2.90 | 1.50 ↓ | 3.60 | 1.90 ↓ | 5.00 | 3.40 | 3.30 | 1.60 ↓ | 4.80 |
Lymphocyte count (× 109 cells/L) | 1.06 | 2.04 | 1.77 | 1.35 | 2.57 | 2.49 | 2.19 | 1.54 | 2.68 |
Red blood cell count (× 1012 cells/L) | 4.81 | 3.91 | 5.58 ↑ | 4.65 | 5.54 ↑ | 5.22 | 5.57 ↑ | 5.02 | 4.77 |
Hemoglobin (g/dL) | 151.0 | 121.0 | 168.0 ↑ | 148.0 | 155.0 | 141.0 | 157.0 | 145.0 | 141.0 |
Hematocrit (%) | 45.70 | 36.30 ↓ | 49.50 | 43.60 | 47.20 | 44.10 | 48.00 | 45.30 | 43.00 |
Platelet count (× 109 cells/L) | 177 | 200 | 219 | 192 | 203 | 234 | 191 | 206 | 226 |
Prothrombin time (s) | 9.10 ↓ | 11.30 | 12.20 | 12.20 | 12.10 | 12.00 | 10.60 | 12.10 | 11.00 |
Activated partial thromboplastin time (s) | 23.90 | 28.20 | 30.40 | 34.80 | 26.40 | 26.20 | 25.40 | 22.90 | 25.30 |
International normalized ratio | 0.78 ↓ | 0.97 | 1.05 | 1.05 | 1.04 | 1.04 | 0.91 | 1.04 | 0.95 |
Fibrinogen (g/L) | 2.08 | 1.65 ↓ | 2.00 | 1.86 ↓ | 2.02 | 2.67 | 1.93 ↓ | 2.52 | 2.10 |
Total protein (g/L) | 66.1 | 67.2 | - | 69.3 | 74.1 | 75.0 | 63.9 ↓ | 76.4 | 72.0 |
Albumin (g/L) | 45.5 | 44.1 | - | 46.8 | 48.1 | 48.1 | 44.4 | 46.6 | 49.9 |
Pre-albumin (mg/L) | 392 | 164 ↓ | - | 285 | 230 | 245 | 284 | 258 | 317 |
Alanine aminotransferase (U/L) | 19 | 6 | - | 9 | 32 | 22 | 43 | 19 | 38 |
Aspartate aminotransferase (U/L) | 20 | 20 | 34 | 14 | 28 | 21 | 32 | 20 | 28 |
Alkaline phosphatase (U/L) | 55 | 50 | - | 90 | 93 | 49 | 104 | 52 | 97 |
Total bilirubin (μmol/L) | 11.3 | 13.6 | - | 12.6 | 18.7 | 14.1 | 11.9 | 9.6 | 5.0 |
Direct bilirubin (μmol/L) | 1.9 | 2.8 | - | 2.8 | 4.0 | 3.0 | 2.5 | 1.8 | 0.7 |
Serum creatinine (μmol/L) | 66.5 | 57.3 | 82.3 | 57.6 | 80.4 | 88.1 | 67.6 | 76.5 | 91.9 |
Blood urea nitrogen (mmol/L) | 3.38 | 2.87 | 4.71 | 4.60 | 5.31 | 6.10 | 2.46 ↓ | 5.13 | 6.36 |
Creatine kinase (U/L) | 60 | 105 | 64 | 61 | 104 | 59 | 89 | 58 | 240 ↑ |
Lactate dehydrogenase (U/L) | 134 | 136 | 159 | 123 | 149 | 115 | 154 | 144 | 176 |
Potassium (mmol/L) | 3.94 | 3.82 | 4.76 | 4.01 | 4.19 | 3.96 | 5.34 ↑ | 4.27 | 4.76 |
Sodium (mmol/L) | 145.5 | 144.7 | 144.1 | 142.4 | 144.7 | 140.7 | 145.1 | 143.3 | 142.8 |
Calcium (mmol/L) | 2.31 | 2.36 | 2.47 | 2.37 | 2.49 | 2.40 | 2.39 | 2.49 | 2.53 |
Chloride (mmol/L) | 105.0 | 109.3 | 102.6 | 100.0 | 101.3 | 105.9 | 102.6 | 102.3 | 102.3 |
C-reactive protein (mg/L) | - | - | 0.60 | 0.31 | 1.67 | - | 0.23 | - | 0.91 |
Procalcitonin (ng/mL) | 0.044 | 0.046 | 0.039 | - | 0.074 ↑ | 0.055 ↑ | 0.033 | 0.055 ↑ | < 0.01 |
Erythrocyte sedimentation rate (mm/h) | - | 8 | 3 | 4 | 6 | 11 | 8 | 37 ↑ | 2 |
SARS-CoV-2 testing | |||||||||
1st sampling date | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 28 |
1st sampling result | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
2nd sampling date | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 29 |
2nd sampling result | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
Date of discharged to home isolation | Jan 31 | Feb 1 | Feb 1 | Jan 31 | Jan 31 | Jan 31 | Feb 1 | Jan 31 | Jan 31 |
Discussion
- Li Q.
- Guan X.
- Wu P.
- et al.
- Li Q.
- Guan X.
- Wu P.
- et al.
- Li Q.
- Guan X.
- Wu P.
- et al.
- Li Q.
- Guan X.
- Wu P.
- et al.
- Zhu N.
- Zhang D.
- Wang W.
- et al.
- Li Q.
- Guan X.
- Wu P.
- et al.
World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance. 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-humancases-20200117 accessed on Feb 20, 2020.
Center for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for 2019 novel coronavirus (2019-nCoV). 2020. https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinical-specimens.html accessed on Feb 20, 2020.
Conclusion
Declaration of Competing Interest
Author contributions
Funding/support
Role of the funders/sponsors
Data sharing
Acknowledgments
Appendix. Supplementary materials
References
- Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia.New Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2001316
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020; (London, England)S0140-6736(20)30183-5
- A novel coronavirus from patients with pneumonia in china, 2019.New Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2001017
- Clinical characteristics of coronavirus disease 2019 in china.New Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2002032
- A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster.Lancet. 2020; (London, England)S0140-6736(20)30154-9
- Importation and human-to-human transmission of a novel coronavirus in vietnam.New Engl J Med. 2020; https://doi.org/10.1056/NEJMc2001272
- Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China.JAMA. 2020; https://doi.org/10.1001/jama.2020.1623
- Transmission of 2019-ncov infection from an asymptomatic contact in Germany.New Engl J Med. 2020; https://doi.org/10.1056/NEJMc2001468
Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was flawed.2020. https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-coronavirus-wrong accessed on Feb 20, 2020.
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study.Lancet. 2020; (London, England)S0140-6736(20)30211-7
- Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.JAMA. 2020; https://doi.org/10.1001/jama.2020.1585
World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. 2020. https://www.who.int/publications-detail/clinical-managementof-severe-acute-respiratoryinfection-when-novelcoronavirus-(ncov)-infection-is-suspected accessed on Feb 20, 2020.
China National Health Commission. New coronavirus pneumonia prevention and control program (4th edition). 2020. http://www.gov.cn/zhengce/zhengceku/2020-01/28/5472673/files/0f96c10cc09d4d36a6f9a9f0b42d972b.pdf accessed on Feb 20, 2020.
- Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome.Clin Infect Diseas Offic Publ Infect Diseases Soc Am. 2004; 38: 467-475
- Middle east respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing sars-like disease.Clin Microbiol Rev. 2015; 28: 465-522
World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance. 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-humancases-20200117 accessed on Feb 20, 2020.
- Detection of 2019 novel coronavirus (2019-ncov) by real-time RT-PCR.Euro Surveill Bull Eur Sur Les Maladies Transmissibles Eur Commun Disease Bull. 2020; 252000045
Center for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for 2019 novel coronavirus (2019-nCoV). 2020. https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinical-specimens.html accessed on Feb 20, 2020.
- Information for laboratories.Novel Coronavirus. 2020; (Wuhan, China)
- A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster.Lancet. 2020; 395 (London, England): 514-523